Back to Search
Start Over
Addendum to Letter to the Editor: Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1
- Source :
- Blood cells, moleculesdiseases. 77
- Publication Year :
- 2019
- Subjects :
- Pediatrics
medicine.medical_specialty
Letter to the editor
Pyrrolidines
Treatment outcome
MEDLINE
Disease
03 medical and health sciences
0302 clinical medicine
First line therapy
Medicine
Humans
Enzyme Inhibitors
Molecular Biology
0303 health sciences
Gaucher Disease
business.industry
030305 genetics & heredity
Authorization
Addendum
Cell Biology
Hematology
Treatment Outcome
Molecular Medicine
business
030217 neurology & neurosurgery
Eliglustat
Subjects
Details
- ISSN :
- 10960961
- Volume :
- 77
- Database :
- OpenAIRE
- Journal :
- Blood cells, moleculesdiseases
- Accession number :
- edsair.doi.dedup.....e04a28051438e387cba79f37c255cd7e